CA‐549: A new tumor marker for patients with advanced breast cancer

Laurence Demers, Harold Harvey, Jerry D. Glenn, Pramod K. Gaur

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


A murine monoclonal antibody, BC4E 549, an IgG1 adapted as tracer antibody in a sandwich immunoradiometric assay, was used to detect a circulating breast cancer‐associated antigen, CA‐549, in patients with advanced breast cancer. The study was designed to examine the specificity and sensitivity of CA‐549 measurements as a specific circulating marker for breast cancer. In a population of 100 normal pre‐and postmenopausal women, serum levels ranged from 1–10 μ/ml. In contrast, 38 of 46 patients (83%) with active, advanced‐stage breast cancer had circulating levels in excess of 10 μ/ml, and levels in several patients exceeded 100 μ/ml. Patients on adjuvant therapy with breast cancer in remission, patients with benign breast disease, and patients with cancers of other sites such as colorectal, ovarian, and lung cancer did not show significant elevations (>10 μ/ml, P > 0.001) of this circulating antigen. Measurement of this breast cancer associated antigen may be of use in the evaluation of treatment for patients with advanced stage breast cancer.

Original languageEnglish (US)
Pages (from-to)168-173
Number of pages6
JournalJournal of Clinical Laboratory Analysis
Issue number3
StatePublished - 1988

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Hematology
  • Public Health, Environmental and Occupational Health
  • Clinical Biochemistry
  • Medical Laboratory Technology
  • Biochemistry, medical
  • Microbiology (medical)


Dive into the research topics of 'CA‐549: A new tumor marker for patients with advanced breast cancer'. Together they form a unique fingerprint.

Cite this